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Abstract
Background: Fibroblast growth factor (FGF)-21 is a novel regulator of glucose and lipid metabolism. Recently, increased
FGF-21 mRNA expression in muscle was found in patients with type 2 diabetes, but the role for FGF-21 in muscle is not well
understood. Patients with HIV-infection and lipodystrophy are characterised by various degree of lipid-driven insulin
resistance. We hypothesized that muscle FGF-21 mRNA would be altered in HIV patients with lipodystrophy.
Design: Twenty-five HIV-infected men with lipodystrophy (LD) and 15 age-matched healthy controls, received an oral
glucose tolerance test and a euglycemic-hyperinsulinemic clamp (50 mU/m2/min) combined with 6,6-H2 glucose infusion.
Muscle biopsies were obtained and FGF-21 mRNA and glycogen synthase (GS) activity were measured.
Results: Subjects with HIV were insulin resistant compared with non-HIV subjects. Compared to controls, HIV subjects
demonstrated a twofold increase of plasma FGF-21 from 70.4656.8 pg/ml vs 109.1671.8 pg/ml, respectively (p = 0.04) and
an eight-fold increase in muscular FGF-21 mRNA expression (p = 0.001). Muscle FGF-21 mRNA correlated inversely with the
rate of disappearance of glucose during insulin clamp (r =20.54, p = 0.0009), and the GS fractional velocity in muscle
(r =20.39, p = 0.03), and directly with fasting insulin (r = 0.50, p = 0.0022), HOMA-IR (r = 0.47, p = 0.004), triglycerides (r = 0.60.
P = 0.0001), waist-to-hip ratio (r = 0.51, p = 0.0001) and limb fat mass (20.46, p = 0.004), but not to plasma FGF-21.
Conclusion: FGF-21 mRNA is increased in skeletal muscle in HIV patients and correlates to whole-body (primarily reflecting
muscle) insulin resistance, but not to plasma FGF-21. Those findings add to the evidence that FGF-21 is a myokine and may
suggest that muscle FGF-21 is working in a local manner.
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Introduction
Fibroblast growth factor (FGF)-21 is a circulating hormone-like
cytokine and has received much attention as a regulator for
glucose and lipid metabolism in liver under fasting and ketotic
conditions[1].
The majority of studies investigating the role of FGF-21 are
based on animal studies. In rodents FGF-21 is produced mainly by
the liver and adipose tissue. In murine models, FGF-21 is reducing
plasma glucose, insulin, triglycerides, LDL and HDL cholesterol
[2,3]. Furthermore, in diet-induced obesity in mice, FGF-21 is
enhancing insulin-mediated suppression of endogenous glucose
production and enhancing insulin-mediated glucose uptake in
skeletal muscle [3]. In lipid metabolism, FGF-21 induces
ketogenesis during starvation [4], promotes fatty acid oxidation
[5] and lipolysis in adipose tissue [6] in rodents.
Paradoxically, circulating FGF-21 is increased in obese nondi-
abetic subjects [7] and in newly diagnosed type 2 diabetes, where it
correlates positively with adiposity and fasting insulin [8]. One
human study has shown that plasma FGF-21 concentrations
correlate with both hepatic as well as with whole-body (muscle)
insulin resistance [9].
Recently, FGF-21 was identified as a novel myokine in humans
[10]. An elevated muscular expression of FGF-21 was found in
patients with type 2 diabetes [11] and insulin was identified as a
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stimulator of muscle-FGF-21 in two separate studies [10,12].
However, little information is available on FGF-21 in muscle and
its role in metabolism
A syndrome of lipodystrophy, characterised by subcutaneous fat
loss, and a relative increase in central fat accumulation, develops
in a subgroup of HIV patients, when treated with highly active
combination antiretroviral therapy (HAART) that includes thy-
midine nucleoside analogues (NA) [13]. Lipodystrophy is associ-
ated with severe metabolic side effects, including dyslipidemia,
hepatic insulin resistance, and lipid-driven impaired insulin-
stimulated glucose uptake in muscle [14–16]. Recently, circulating
FGF-21 was observed in HIV-infected patients, and especially
those with lipodystrophy (11). This increase was, furthermore,
closely associated with insulin resistance.
Since HIV patients with lipodystrophy share the same
metabolic disturbances as subjects with type 2 diabetes we aimed
to determine whether muscle FGF-21 mRNA is altered in these
patients. The second aim of the study was to investigate the
possible association of muscle FGF21 mRNA with other measures
of adiposity and insulin resistance, including peripheral insulin
resistance by using an insulin clamp combined with stable isotopes.
Patients and Methods
Patients
Twenty-three HIV-infected men were recruited from the
outpatient clinic of the Department of Infectious Disease,
Rigshospitalet in Copenhagen. LD was defined clinically by
physical examination of peripheral lipoatrophy (defined by the
presence of peripheral lipoatrophy with at least one moderate sign
of fat loss in face, arms, buttocks, or legs based on a physical
examination by a single investigator (BL) using a validated
questionnaire developed by Carr et al. [17]. Some of the subjects
have been included in a former study [18]. All patients were on a
stable and effective nucleoside analogue based HAART with no
changes in antiretroviral therapy during the preceding 8 weeks.
Fifteen age-matched HIV-negative healthy men served as controls.
Demographic data were collected for each patient: age, duration
of HIV infection, duration and types of all antiretroviral therapy,
weight, height, CD4 count, HIV-RNA copies. Inclusion criteria
were: no signs of ongoing infections; fasting glucose under
7 mmol/L and 120 min glucose after an OGTT below
11.1 mmol/L, no dyslipidemia (triglycerides .1.7 mmol/L and/
or HDL-cholesterol ,0.9 mmol/L); suppressed viral load (,20
copies/mL). Exclusion criteria were: Severe cardiovascular
diseases; arthritis; severe neuropathy; opportunistic infections that
required hospitalisation within the last 6 weeks; diabetes (fasting
glucose $7 mmol/L or 2-hrs. glucose .11 mmol/L after an
OGTT); hepatitis C; concurrent therapy with antidiabetic agents,
anticoagulant or any hormones. Fifteen age- and VO2max -
matched HIV-seronegative healthy men served as controls. The
control subjects have been included in a former a study [18].
Written informed consent was obtained from all subjects
according to the requirements from the local ethical committee
and the Helsinki Declaration II, and the approval from the local
ethical committee (The Ethics Committee of Copenhagen and
Frederiksberg) was obtained.
Biochemical measurements
Peripheral blood samples were obtained after an overnight
fasting at 8 A.M.. Measurements of total cholesterol (mmol/L),
HDL-cholesterol (mmol/L), LDL-cholesterol (mmol/L), triglycer-
ids (mmol/L), plasma glucose (mmol/L), insulin (pmol/L), were
determined immediately using routine methods.
CD4 cell counts were calculated by flowcytometry and HIV-
RNA copies were measured by the Amplicor HIV Monitor (Roche
Molecular Systems, Branchburg, NJ) (lower limit of dectection: 20
copies/ml).
FGF-21 was measured in plasma. Ethylenediaminetetraacetate
(EDTA) was used as an anticoagulant. Plasma samples were stored
at 280 C until analysed. FGF-21 was determined by enzyme-
linked immunosorbent assay (ELISA) kits (Biovendor, Germany).
The detection limits were 15 pg/ml and the interassay coefficient
of variation was 3.9%. All samples and standards were run as
duplicates and the mean of duplicates was used in the statistical
analyses.
RNA analysis and quantitative PCR analysis
RNA was extracted from 20–30 mg of skeletal muscle biopsies
using TriZol (Invitrogen, Carlsbad, CA) and reverse transcribed
using random hexamer primers (TaqMan reverse transcription
reagents; Applied Biosystems). Real-time PCR was performed on
an ABI PRISM 7900 Sequence Detection System (PE Biosystems)
using TaqMan reagents (Applied Biosystems). Sequence-specific
FGF-21 primer/probe sets were used for FGF-21 amplification,
while predeveloped household TaqMan primer/probe sets (Ap-
plied Biosystems) were used for 18S detection. The relative
expression of FGF-21 was normalized to the endogenous control
and expressed as FGF-21 expression per 18S expression. The
levels of 18S in the skeletal muscle were not different between
groups (data not shown).
Body composition analysis
Fat and fat-free tissue masses for the whole body, trunk and
extremities were measured using dual-energy X-ray absorptiom-
etry (DXA) scanner (Lunar Prodigy, GE Medical Systems
Wisconsin, USA, version 8.8) [17]. Whole-body and regional fat
measurements (trunk and extremity) were determined as previ-
ously described [18].
Insulin sensitivity
Insulin resistance was assessed from several measurements:
fasting plasma insulin, homeostasis model (HOMA-IR) [19] and
area under the curve (AUC) for the insulin concentration during
an 75-g oral glucose tolerance test (OGTT)
Euglycemic-hyperinsulinemic clamp combined with
stable isotope infusion. Diet was registered two days before
the clamp and participants were advised to ingest the same diet at
the end-of–study visit. Subjects were admitted at 0800 h to the
laboratory after an overnight fast (including HAART). An
euglycemic-hyperinsulinemic clamp combined with glucose stable
isotope technique was undertaken as described previously [20]. In
brief, after obtaining baseline blood samples to determine
background glucose enrichment a primed 16 mmol/kg constant
infusion (0.22 mmol/kg/min) of [6,6-2H2]-glucose (Cambridge
Isotopes Laboratories, Inc., MA, USA) was maintained for 5 hrs
to determine glucose kinetics. The clamp was initiated 2.5 hrs after
the start of the isotope infusion (basal condition) and continued for
2.5 hrs, adapted after [21]. Insulin (Actrapid, Novo Nordisk
Insulin), 100 IU/ml was infused at a rate of 50 mU/m2/min
(initiated with a two-step priming dose of 200 mU/m2/min for
5 min followed by 100 mU/m2/min for 5 min). Blood glucose
was maintained at 5.5 mmol/L by infusion of 20% glucose
enriched to 2.5% with [6,6-2H2]-glucose [22]. The infusion of
[6,6-2H2]-glucose was decreased by 75% of basal infusion rate
during insulin-stimulated condition to steadily maintain the
plasma glucose enrichment by accounting for the expected decline
in hepatic glucose production. In the morning, the hand was
Muscle FGF-21,Insulin Resistance and Lipodystrophy
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wrapped in a heating blanket to obtain arterialised blood samples
every 10 min during the last 30 min of the basal and insulin-
stimulated conditions to determine plasma glucose concentrations
and tracer-to-tracee ratio.
Glycogen synthesis activity
GS activity was measured in muscle homogenates by using a
Unifilter 350 microtiter plate assay (Whatman; Frisenette,
Ebeltoft, Denmark) as described by Thomas et al.[23]. Glycogen
synthase activity is expressed as fractional velocity (%FV)
corresponding to GS activity at a subsaturating (0.17 mM) G-6-
P concentration divided by GS activity at a saturating (8 mM)
concentration of G-6-P.
Calculations
A physiological and isotopic steady state was achieved during
the last 30 minutes of the basal and the insulin-stimulated
conditions, so the rates of endogenous glucose appearance (Ra)
and disappearance of glucose (Rd) were calculated as the tracer
infusion rate divided by the tracer to-tracee ratio as previously
described [20]. Glucose Ra and Rd are expressed per kg body
weight (mmol?kg bwt21?min2).
Statistical analysis
Statistical calculations were performed using SAS 9.1 (USA).
Data are presented as means +/2 SD. P,0.05 was considered
significant in all analyses. Rd and Ra, Insulin, triglycerides, FFA,
HDL-cholesterol, LDL-cholesterol, and FGF-21 were natural log-
transformed to achieve an approximate normal distribution and
equal variance. Parameters between HIV-infected patients and
healthy controls were compared with unpaired t-test. Pearson’s
correlations were used to examine the relationship between muscle
FGF-21 or plasma FGF-21 levels and markers of insulin sensitivity,
as well as with anthropometric parameters.
Results
Baseline characteristics
Demographic, body composition and biochemical data appear
from Table 1. The healthy men and the HIV-infected patients
were matched on age and physical activity. All subjects were
categorised as sedentary-normal active. HIV-infected patients
displayed a redistribution of body fat as the percentage of fat on
the limb were lower and the percentage of fat in the trunk was
higher compared to control subjects. The patients also had
disturbances in their lipid metabolism as fasting triglycerides and
total-cholesterol levels were higher, and HDL-cholesterol level was
lower. In addition, compared to controls, the HIV-infected
patients were characterized by peripheral insulin resistance as
whole-body insulin-stimulated glucose uptake (Rd) and incremen-
tal glucose uptake (Rd basal – Rd clamp) were decreased.
Furthermore, the HIV subjects had higher basal endogenous
glucose production, lower insulin-mediated suppression of endog-
enous glucose production (Ra), but no difference in the incremen-
tal suppression of endogenous glucose production during the
clamp (Ra basal – Ra clamp) as compared to control subjects.
Plasma FGF-21 and FGF-21mRNA in muscle
Plasma FGF-21 was elevated in the HIV-group compared to
healthy controls (70.4656.8 pg/ml vs 109.1671.8 pg/ml, respec-
tively) (P = 0.04) (Figure 1A).
FGF-21 mRNA expression in skeletal muscle was increased 8-
fold in patients with HIV relative to healthy individuals
(P,0.0001, parametric statistics, and p= 0.0002 for non-para-
metric statistics) (Figure 1B). The association between plasma
FGF-21 and muscle FGF-21 did not reach statistical significance
(r = 0.32; p= 0.056).
Relationships between FGF-21 mRNA, plasma FGF-21
and insulin resistance
Muscle FGF-21 mRNA correlated positively to all markers of
insulin resistance: fasting insulin (r = 0.57, p = 0.0008), homeostasis
model assessment (HOMA) score (r = 0.55, p = 0.001), and
insulinAUC (r = 0.38, p = 0.02) (Fig. 1 C–F).
To test whether the association between insulin and FGF-21
mRNA in muscle reflect an association with peripheral or hepatic
insulin resistance, we performed a euglycemic-hyperinsulinemic
clamp with stable isotopes. We found that muscle FGF-21 mRNA
was negatively associated with the insulin-mediated glucose-uptake
(Figure 1G), but not with hepatic insulin resistance (data not
shown).
We did not find any association between plasma FGF-21 and
parameters of insulin resistance (fasting insulin, plasma glucose,
HOMA-IR, glucose AUC, Insulin AUC, Ra or Rd). However, when
investigating by group, plasma FGF-21 correlated positive with
insulin stimulated glucose-uptake in healthy subjects but not in the
HIV patients (r = 0.51, p = 0.049) (data not shown).
Previous studies have demonstrated that insulin resistance in
patients with HIV-LD are associated with decreased insulin-
stimulated glycogen synthase (GS) activity [24]. Therefore, we
measured GS activity. The GS fractional velocity of % total GS
activity was lower in HIV patients compared with healthy controls
(2861.3; 3561.6, respectively) in the basal stage. GS fractional
velocity is known to correlate positively with the glucose Rd [25].
As high FGF-21 mRNA in muscle is associated with low rate of
disappearance of glucose, this could be linked to low GS fractional
velocity in muscle. In accordance with this hypothesis, we found
that high levels of FGF-21 mRNA in muscle were associated with
decreased GS fractional velocity in muscle (Fig. 1H).
Relationships between muscle FGF-21 mRNA, and fat
distribution and lipids
We found a strong negative association between muscle FGF-21
mRNA and the amount of subcutaneous fat (limb fat mass)
(r =20.46; p = 0.0038) and positive association with trunk-limb-
fat-ratio (r = 0.51; p = 0.001) and triglycerides (r = 0.56;
p = 0.0003). FGF-21 mRNA was not associated with total fat
mass or total trunk fat (data not shown).
Discussion
The novelty and the major findings of our study is that we
demonstrate for the first time that FGF-21 mRNA expression is
increased in skeletal muscle in patients with HIV-LD compared to
healthy age-matched men and that muscle FGF-21 mRNA
correlates negatively with the rate of insulin-stimulated glucose
disappearance (primarily reflecting muscle). Furthermore, in-
creased FGF-21 mRNA expression in muscle is associated with
decreased limb fat mass, increased waist-to-hip ratio and increased
triglycerides.
Only three studies are published on expression of FGF-21 in
muscle in humans [10,12,26] and very little is known about the
function of muscle FGF-21. Our result is in agreement with a
previous study, in which FGF-21 mRNA was found to be
increased in muscle from subjects with type 2 diabetes and the
expression was increased by hyperinsulinemia [10]. However, this
study did not distinguish between hepatic and peripheral insulin
sensitivity as we do in the present study. Vienberg et al. [12] also
Muscle FGF-21,Insulin Resistance and Lipodystrophy
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Table 1. Baseline characteristics of patients and healthy controls.
HIV patients (n=23) Healthy controls (n=15)
Age (years) 47.9 (9.5) 47.5 (6.1)
Duration of HIV infection (years) 15.6 (9.6)
Duration of antiretroviral therapy (years) 10.3 (4.3)
CD4+ cell (cells/ml) 558 (208)
LogHIV-RNA (copies/ml) 1.33 (0.12)
Antiretroviral use
NNRTI-based HAART, PI-based HAART, NNRTI-,PI-based HAART regime, No. 12/14/2
Current Thymidine-NRTI use, No. (%) 11 (47.8)
Current PI use, No. (%) 13 (56.7)
Current NNRTI use, No. (%) 11 (47.8)
Physical activity parameters
VO2max (LO2/min) 2.3 (0.5) 2.5 (0.6)
Body composition
Body-mass index (kg/m2) 23.7 (2.9) 23.7 (1.9)
Weight (kg) 73.6 (11.2) 76.9 (7.4)
Waist (cm) 93.6 (6.4) 90 (5.7)
Waist-to.hip ratio 1.01 (0.04) 0.94 (0.03)
Fat mass (kg) 13.8 (5.3) 15.7 (4.4)
Trunk fat mass (kg) 9.8 (3.9) 8.9 (3.0)
Trunk fat percentage (%) 71.2 (6.2) **** 56.1(5.2)
Limb fat mass (kg) 3.5 (1.6)**** 6.2 (1.5)
Limb fat percentage (%) 25.1 (6.1) **** 40.2 (4.9)
Trunk-to-limb fat ratio 3.09 (1.17)* 1.4 (0.29)
Lean mass (kg) 57.0 (6.8) 58.2 (5.2)
Metabolic parameters
Total-cholesterol (mmol/L) 5.5 (0.9)** 4.63 (0.64)
HDL-C (mmol/L) 1.23 (0.52)* 1.51 (0.32)
LDL-C (mmol/L) 3.7 (0.9) 3.3 (0.6)
Triglycerides (mmol/L) 2.55(1.43)**** 0.76 (0.24)
Glucose (mmol/L) 5.4 (0.6) 5.2 (0.3)
Insulin (pmol/L) 52 (25)**** 25 (8.9)
HOMA-IR 2.2 (1.4)**** 0.99 (0.37)
Insulin sensitivity
Rate of appearance (mmol glucose/kg/min)
Basal 14.2 (0.49)*** 11.8 (2.0)
Clamp 6.4 (1.8)** 4.0 (2.5)
Delta{ 7.8 (2.1) 7.8 (1.9)
Rate of disappearance (mmol glucose/kg/min)
Basal 14.2 (0.49)*** 11.8 (2.0)
Clamp 40.2 (9.9)** 48.6 (8.4)
Delta{ 26.02 (10.1)** 36.81 (7.14)
Glucose tolerance
Glucose area under the curve (mmol/Lmin) 826 (200)* 670 (126)
Insulin area under the curve (pmol/Lmin) 52360 (31017)** 23505 (10598)
Data are presented as mean (SD).
{Delta, differences between clamp and basal values. HAART, highly active antiretroviral therapy; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor;
NNRTI, non- nucleoside reverse transcriptase inhibitor. HOMA-IR, homeostatic model assessment for insulin resistance, Rate of appearance and disappearance, Rate of
appearance and disappearance of glucose during a euglycemic-hyperinsulinemic clamp performed in both HIV patients and healthy controls.
*P,0.05;
**P,0.01;
***P,0.001,
****P,0.0001 by t-test.
doi:10.1371/journal.pone.0055632.t001
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Figure 1. FGF-21 mRNA are increased in muscle from subjects with HIV-lipodystrophy and correlates to several measurement of
insulin resistance. (A) Fasting plasma levels of fibroblast growth factor (FGF) 21 are increased 2-fold in HIV subjects with lipodystrophy compared
to healthy men; (B) mRNA expression of FGF-21 are increased 8-fold in muscle biopsies from HIV subjects with lipodystrophy compared to healthy
men; (C–F) Plots of FGF-21 mRNA in muscle versus several measurements of insulin resistance: FGF-21 mRNA in muscle are positively correlated to
fasting insulin (C), HOMA-IR (D), Area under the curve for insulin during an oral glucose tolerance test (E), Area under the curve for C-peptide during
an oral glucose tolerance test (F), and negatively correlated to the incremental rate of disappearance of glucose (G), and fractionel velocity of
glycogen synthesis (H) in healthy (e) and HIV subjects with lipodystrophy (N). In the dot plots data for each subjects are given and the line represent
means. * P,0.05 and ***P,0.001 for healthy vs HIV-lipodystrophy patients. For plots, linear regression lines, correlations coefficient, and significance
levels are given for all subjects.
doi:10.1371/journal.pone.0055632.g001
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find that FGF-21 mRNA was expressed in muscle, but they find no
activation of muscle FGF-21 mRNA by a short term high fat
overfeeding. In the study by Mashili et al. [26], FGF-21 mRNA
was expressed in skeletal muscle, but no difference was found
between obese subjects with normal glucose tolerance and obese
subjects with Type 2 diabetes. However, in this study no healthy
non-obese subjects were included.
A body of evidence show that in murine models FGF-21 lowers
blood glucose, insulin, triglycerides, fat mass and increases insulin
sensitivity [2,3]. In humans, circulating FGF-21 is increased in
obesity and in subjects with type 2 diabetes [7,8]. Therefore,
increased levels of circulating FGF-21 have been suggested to be a
compensatory mechanism due to insulin resistance or a sign of
FGF-21 resistance. In murine models, chronic administration of
FGF-21 increases insulin-mediated glucose uptake in muscle, but
only in diet induced obesity [3]. Furthermore, triglycerides deposit
in muscle by FGF-21 administration is attenuated. Therefore, it
has been suggested that the effect of FGF-21 on muscle is
secondary to other events e.g. lipid toxicity in muscle.
Besides the strong correlation between insulin-mediated glucose
uptake and FGF-21 mRNA in muscle, FGF-21 mRNA was also
tightly correlated to triglycerides. Patients with HIV lipodystrophy
have increased lipolysis and high triglycerides as wells as an
increased amount of intra myocellular lipid accumulation [27].
We have previously shown that HIV patients display lipid driven
insulin resistance [20]. Therefore, increased FGF-21 in muscle
may be a compensatory mechanism to offset the lipid-induced
insulin resistance in muscle. This explanation is supported by in
vitro models, where FGF-21 is found to protect human myotubes
from palmitate-induced insulin resistance [28], and to increase
basal and insulin-stimulated glucose uptake in human myotubes
[26].
In rodents, FGF21 has emerged as a hormone involved in
energy homeostasis in the liver. We found lower fractional
glycogen synthase activity in muscle in the patients indicating
reduced capacity for deposition of glucose into glycogen in the
muscle during basal condition. Furthermore, FGF-21 mRNA was
associated with low fractional glycogen synthase activity in muscle.
Therefore, in accordance to the role of FGF-21 in the liver in
rodent, muscular FGF-21 in humans may be a marker of the
substrate and energy levels in the muscle. Since our observations
are cross-sectional in nature it is not possible to establish cause-
and-effect relationship.
In line with FGF-21 as an energy sensor, the increased FGF-21
mRNA in muscle may be speculated to be related to mitochon-
drial dysfunction. Mice with late-onset mitochondrial myopathy
show induction of FGF-21 in their muscles, which is closely related
to the number of COX-negative muscle fibres [29], suggesting that
mitochondria deficiency in skeletal muscle induces FGF21
expression. In skeletal muscle, HIV patients treated with NRTI
have a reduced mitochondrial/nucleus DNA ratio, more frequent
mtDNA deletions and possibly more COX-deficient muscle fibres
than HIV-negative controls [30]. In addition, mitochondrial aging
was recently found to be accelerated by anti-retroviral therapy
through the clonal expansion of mtDNA mutations [31].
Therefore, the increase in FGF-21 could also be related to
mitochondrial changes in the muscle.
Very little information on FGF receptors in humans exists.
FGF21 acts through the interaction with specific FGF receptors
and a cofactor called b-Klotho [32]. FGFR1 in adipose tissue has
been suggested as the main receptor/tissue to serve to mediate the
effect of FGF21 in vivo in rodents [33]. A very recent paper has
shown a dramatically reduction of b-klotho mRNA in adipose
tissue in HIV-patients with and without lipodystrophy [33],
supporting the hypothesis that the increase in muscle FGF-21
mRNA may in part be a compensatory mechanism to the reduced
FGF-21 signalling in adipose tissue and that adipose tissue may be
target tissue for FGF21 in HIV-patients. A FGF-21 receptor in
muscle has not yet been defined. As mentioned, FGF21 has direct
effects in enhancing skeletal muscle glucose uptake in both rodents
and human myocytes [3,26] and protects human myotubes from
palmitate-induced insulin resistance [28], demonstrating that
FGF-21 signals directly in muscle.
In agreement with Domingo et al. [34], we found increased
circulating FGF-21 in HIV patients with lipodystrophy. However,
in contrast to their study we did not find a correlation between
plasma FGF-21 and measures of insulin resistance (fasting insulin,
HOMA-IR, area under the curve for insulin during an OGTT
and rate of glucose disappearance during an euglycemic-hyperin-
sulinemic clamp combined with stable isotopes). The explanation
for this discrepancy is difficult to understand. The subjects in the
study by Domingo et al. included naive, HAART- treated patients
with or withour lipodystophy and a control group. The HIV study
groups were comparable with regards to the range of circulating
FGF-21, age, CD4 count and BMI. The HIV-patients in our study
were more insulin resistant (HOMA 2.2 vs 1,7 in the study by
Domingo et al. ), had a higher trunk-to-limb ratio (3.09 vs 2.42),
and had more hyperlipidemia (TC 5.5 vs 5.07, Triglyceriedes 2.55
vs 5.00) than the HIV subjects with lipodystrophy in the study by
Domingo et al. In our study no patients were co-infected with
hepatitis C or had chronic hepatitis B virus infection, whereas this
was the case for 7.6% and 8.9% , respectively in the patients in the
study by Domingo et al. In the study by Domingo et al, circulating
FGF-21 was tightly correlated with markers of liver function such
as AST, ALT and GGT. We did not measure AST, ALT or GGT
and can therefore not speculate whether this could explain the
discrepancy between the studies.
We did not find a significant correlation between high levels of
circulating FGF-21 levels and FGF-21 mRNA in muscle,
indicating that muscle is not the major source of circulating
FGF-21. As previously suggested some evidence exists that liver
may be the primary source of circulating FGF-21. The lack of
association between circulating and muscle-expressed FGF-21 also
suggests that muscle FGF-21 primarily works in a local manner
regulating glucose metabolism in the muscle and/or signals to the
adipose tissue in close contact to the muscle.
Our study has some limitations. The number of subjects is small
and some correlations could have been significant with greater
statistical power. Another aspect is that protein levels of FGF-21
were not determined in the muscles extracts, consequently we
cannot be sure the increase in FGF-21 mRNA is followed by
increased protein expression.
In conclusion, we show that FGF-21 mRNA is increased in
skeletal muscle in HIV patients and that FGF-21 mRNA in muscle
correlates to whole-body (primarily reflecting muscle) insulin
resistance. These findings add to the evidence that FGF-21 is a
myokine and that muscle FGF-21 might primarily work in an
autocrine manner.
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